Smith & Nephew plc (SN.) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.26 M

Shareholding (Jun 2024)

FII

0.01%

Held by 1 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROCE of 22.98%

Poor long term growth as Operating profit has grown by an annual rate 3.16% of over the last 5 years

Flat results in Jun 25

With ROE of 9.45%, it has a expensive valuation with a 2.90 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

GBP 10,467 Million (Large Cap)

P/E

31.00

Industry P/E

Dividend Yield

590.13%

Debt Equity

0.48

Return on Equity

9.45%

Price to Book

2.59

Revenue and Profits:

Net Sales:

789 Million

(Quarterly Results - Dec 2014)

Net Profit:

101 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.34%

6 Months

13.82%

1 Year

23.74%

2 Years

18.93%

3 Years

13.03%

4 Years

0.12%

5 Years

-17.43%

Smith & Nephew plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Smith & Nephew Hits Day Low of GBP 12.17 Amid Price Pressure

Smith & Nephew plc, a key player in the Pharmaceuticals & Biotechnology sector, saw its stock decline significantly today, reaching an intraday low. Despite recent challenges, the company maintains a strong market capitalization and has shown resilience with a notable yearly return, outperforming the FTSE 100.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.08%

EBIT Growth (5y)

3.16%

EBIT to Interest (avg)

67.31

Debt to EBITDA (avg)

0.43

Net Debt to Equity (avg)

0.49

Sales to Capital Employed (avg)

0.43

Tax Ratio

29.67%

Dividend Payout Ratio

78.32%

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

22.98%

ROE (avg)

18.53%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.90

EV to EBIT

23.51

EV to EBITDA

16.24

EV to Capital Employed

2.29

EV to Sales

4.86

PEG Ratio

Dividend Yield

765.22%

ROCE (Latest)

9.73%

ROE (Latest)

9.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'14 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2014 is 8.69% vs 8.23% in Dec 2013",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2014 is 1.00% vs 13.24% in Dec 2013",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'14",
        "Dec'13",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "789.00",
          "val2": "725.90",
          "chgp": "8.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "273.50",
          "val2": "219.30",
          "chgp": "24.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "13.30",
          "val2": "1.90",
          "chgp": "600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-36.60",
          "val2": "-21.00",
          "chgp": "-74.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "101.10",
          "val2": "100.10",
          "chgp": "1.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "251.40%",
          "val2": "228.90%",
          "chgp": "2.25%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.85% vs 5.44% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 52.36% vs 16.91% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,546.80",
          "val2": "4,464.00",
          "chgp": "1.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,196.60",
          "val2": "1,177.70",
          "chgp": "1.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "117.40",
          "val2": "106.20",
          "chgp": "10.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-230.90",
          "val2": "-397.40",
          "chgp": "41.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "322.40",
          "val2": "211.60",
          "chgp": "52.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "167.60%",
          "val2": "168.90%",
          "chgp": "-0.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'14 - YoY

Dec'14

Dec'13

Change(%)

Net Sales

789.00

725.90

8.69%

Operating Profit (PBDIT) excl Other Income

273.50

219.30

24.72%

Interest

13.30

1.90

600.00%

Exceptional Items

-36.60

-21.00

-74.29%

Consolidate Net Profit

101.10

100.10

1.00%

Operating Profit Margin (Excl OI)

251.40%

228.90%

2.25%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2014 is 8.69% vs 8.23% in Dec 2013

Consolidated Net Profit

YoY Growth in quarter ended Dec 2014 is 1.00% vs 13.24% in Dec 2013

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

4,546.80

4,464.00

1.85%

Operating Profit (PBDIT) excl Other Income

1,196.60

1,177.70

1.60%

Interest

117.40

106.20

10.55%

Exceptional Items

-230.90

-397.40

41.90%

Consolidate Net Profit

322.40

211.60

52.36%

Operating Profit Margin (Excl OI)

167.60%

168.90%

-0.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 1.85% vs 5.44% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 52.36% vs 16.91% in Dec 2023

All Annual Results

Company CV

About Smith & Nephew plc

Smith & Nephew plc

Pharmaceuticals & Biotechnology

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Company Coordinates

Company Details

Building 5, Croxley Park, Hatters Lane , WATFORD None : WD18 8YE

Tel: 44 20 7401764644 20 79602285

http://www.smith-nephew.com/

Registrar Details

Smith & Nephew plc

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROCE of 22.98%

Poor long term growth as Operating profit has grown by an annual rate 3.16% of over the last 5 years

Flat results in Jun 25

With ROE of 9.45%, it has a expensive valuation with a 2.90 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Smith & Nephew Hits Day Low of GBP 12.17 Amid Price Pressure

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'14 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Smith & Nephew plc

Company Coordinates